Editorial : antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply
| Errataetall: |
CommentOn: Aliment Pharmacol Ther. 2018 Sep;48(5):507-522. - PMID 29873091 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 48(2018), 5 vom: 29. Sept., Seite 575-576 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goncalves, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 27.08.2019 Date Revised 27.08.2019 published: Print CommentOn: Aliment Pharmacol Ther. 2018 Sep;48(5):507-522. - PMID 29873091 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.14860 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM287942678 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM287942678 | ||
| 003 | DE-627 | ||
| 005 | 20231225055154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.14860 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0959.xml |
| 035 | |a (DE-627)NLM287942678 | ||
| 035 | |a (NLM)30156326 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goncalves, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Editorial |b antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.08.2019 | ||
| 500 | |a Date Revised 27.08.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Aliment Pharmacol Ther. 2018 Sep;48(5):507-522. - PMID 29873091 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 650 | 7 | |a CT-P13 |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 700 | 1 | |a Magro, F |e verfasserin |4 aut | |
| 700 | 1 | |a Danese, S |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, P L |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Horin, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 48(2018), 5 vom: 29. Sept., Seite 575-576 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2018 |g number:5 |g day:29 |g month:09 |g pages:575-576 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.14860 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2018 |e 5 |b 29 |c 09 |h 575-576 | ||